• Users Online: 217
  • Print this page
  • Email this page
Year : 2021  |  Volume : 4  |  Issue : 1  |  Page : 22-29

FGFR inhibitors: Emerging treatments in advanced or metastatic cholangiocarcinoma

1 Medical Oncology Department, St Vincent’s University Hospital, Dublin, Ireland
2 Medical Oncology Department, Mid-Western Cancer Centre, University Hospital Limerick, Limerick, Ireland

Correspondence Address:
Dr. Yasar Ahmed
Medical Oncology Department, St Vincent’s University Hospital, Merrion Rd, Dublin 4 D04 N2E0.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jco.jco_45_20

Rights and Permissions

Cholangiocarcinoma (CCA) is an aggressive cancer with poor prognosis, where the median overall survival remains less than 1 year with standard treatment for unresectable or metastatic disease. This highlights the need for new therapeutic approaches. The fibroblast growth factor receptor (FGFR) family of transmembrane receptors, which are implicated in tumorigenesis, may represent one such target. In this article, we summarize the therapeutic rationale for targeting these receptors in CCA and the role of molecular testing to identify potential responders to treatment. We examine the current available safety and efficacy data on the several small molecule tyrosine kinase inhibitors under investigation for this disease. With a move toward identifying and targeting tumor specific mutations, FGFR inhibitors represent an exciting development which may be available for patients in the near future.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded110    
    Comments [Add]    

Recommend this journal